

# AI Clinical Research NEWSLETTER



Welcome to the **May** edition of AICR`s Newsletter, where we bring you the latest updates and advancements from our company.


As we strive to push the boundaries of medical innovation, we are excited to share with you some of the research initiatives achieved by our dedicated team.

01/02

#### News

- Ongoing studies
- Future studies
- New partners
- EMA updates





## **Ongoing studies**

In different therapeutic areas: Covid-19, Schizophrenia and RIE-Ther (medical device).

We continued our site management and monitoring activities, effectively assisting both our investigators and patients.

#### **Future studies**

• Studies in the initial stages of start-up and preparation, in two different therapeutic areas: Active Rheumatoid Arthritis & Benign Prostatic Hyperplasia

#### **New partners**

We are proud to announce that AICR is now part of **ACE-REACT** -Alliance for Clinical Excellence in Research and Clinical Trials

• https://www.linkedin.com/company/67748894/admin/feed/posts/

### **EMA updates**

- EMA's human medicines committee (CHMP) recommends to suspend or not grant the marketing authorizations for a number of generic medicines tested by Synapse Labs Pvt. Ltd. The CHMP's recommendation is sent to the European Commission which will issue a legally binding decision in due course.
- <u>https://www.ema.europa.eu/en/medicines/human/referrals/synapse</u>

